Programa de Pós-Graduação em Ciências Médicas, Universidade de Brasília, Brasília, Distrito Federal, Brazil.
Serviço de Dermatologia, Hospital Universitário de Brasília, Universidade de Brasília, Brasília, Distrito Federal, Brazil.
Front Immunol. 2022 Nov 14;13:1004023. doi: 10.3389/fimmu.2022.1004023. eCollection 2022.
The present study applied distinct models of descriptive analysis to explore the integrative networks and the kinetic timeline of serum soluble mediators to select a set of systemic biomarkers applicable for the clinical management of COVID-19 patients. For this purpose, a total of 246 participants (82 COVID-19 and 164 healthy controls - HC) were enrolled in a prospective observational study. Serum soluble mediators were quantified by high-throughput microbeads array on hospital admission (D0) and at consecutive timepoints (D1-6 and D7-20). The results reinforce that the COVID-19 group exhibited a massive storm of serum soluble mediators. While increased levels of CCL3 and G-CSF were associated with the favorable prognosis of non-mechanical ventilation (nMV) or discharge, high levels of CXCL10 and IL-6 were observed in patients progressing to mechanical ventilation (MV) or death. At the time of admission, COVID-19 patients presented a complex and robust serum soluble mediator network, with a higher number of strong correlations involving IFN-γ, IL-1Ra and IL-9 observed in patients progressing to MV or death. Multivariate regression analysis demonstrates the ability of serum soluble mediators to cluster COVID-19 from HC. Ascendant fold change signatures and the kinetic timeline analysis further confirmed that the pairs "CCL3 and G-CSF" and "CXCL10 and IL-6" were associated with favorable or poor prognosis, respectively. A selected set of systemic mediators (IL-6, IFN-γ, IL-1Ra, IL-13, PDGF and IL-7) were identified as putative laboratory markers, applicable as complementary records for the clinical management of patients with severe COVID-19.
本研究应用了不同的描述性分析模型,探索血清可溶性介质的综合网络和动力学时间线,以选择一组适用于 COVID-19 患者临床管理的系统生物标志物。为此,共纳入 246 名参与者(82 名 COVID-19 患者和 164 名健康对照者[HC])进行前瞻性观察性研究。入院时(D0)和连续时间点(D1-6 和 D7-20)通过高通量微珠阵列定量测定血清可溶性介质。结果强化了 COVID-19 组表现出大量的血清可溶性介质风暴。虽然 CCL3 和 G-CSF 水平升高与非机械通气(nMV)或出院的良好预后相关,但观察到进展为机械通气(MV)或死亡的患者中 CXCL10 和 IL-6 水平升高。入院时,COVID-19 患者呈现出复杂而强大的血清可溶性介质网络,在进展为 MV 或死亡的患者中观察到更多涉及 IFN-γ、IL-1Ra 和 IL-9 的强相关性。多元回归分析表明,血清可溶性介质能够将 COVID-19 与 HC 区分开来。上升倍数特征和动力学时间线分析进一步证实,“CCL3 和 G-CSF”和“CXCL10 和 IL-6”对分别与良好或不良预后相关。一组选定的系统介质(IL-6、IFN-γ、IL-1Ra、IL-13、PDGF 和 IL-7)被确定为潜在的实验室标志物,可作为严重 COVID-19 患者临床管理的补充记录。